A new Neu—a syngeneic model of spontaneously metastatic HER2-positive breast cancer

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
A new Neu—a syngeneic model of spontaneously metastatic HER2-positive breast cancer ; day:8 ; month:5 ; year:2024 ; pages:1-14
Clinical & experimental metastasis ; (8.5.2024), 1-14

Creator
Baugh, Aaron G.
Gonzalez, Edgar
Narumi, Valerie H.
Kreger, Jesse
Liu, Yingtong
Rafie, Christine
Castanon, Sofi
Jang, Julie
Kagohara, Luciane T.
Anastasiadou, Dimitra P.
Leatherman, James
Armstrong, Todd
Chan, Isaac
Karagiannis, George S.
Jaffee, Elizabeth M.
MacLean, Adam
Torres, Evanthia T. Roussos
Contributor
SpringerLink (Online service)

DOI
10.1007/s10585-024-10289-z
URN
urn:nbn:de:101:1-2407172104373.619844136800
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:45 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Baugh, Aaron G.
  • Gonzalez, Edgar
  • Narumi, Valerie H.
  • Kreger, Jesse
  • Liu, Yingtong
  • Rafie, Christine
  • Castanon, Sofi
  • Jang, Julie
  • Kagohara, Luciane T.
  • Anastasiadou, Dimitra P.
  • Leatherman, James
  • Armstrong, Todd
  • Chan, Isaac
  • Karagiannis, George S.
  • Jaffee, Elizabeth M.
  • MacLean, Adam
  • Torres, Evanthia T. Roussos
  • SpringerLink (Online service)

Other Objects (12)

How We Treat HER2-Positive Metastatic Breast Cancer

How We Treat HER2-Positive Metastatic Breast Cancer

ASCO 2019: highlights in HER2-positive metastatic breast cancer

ASCO 2019: highlights in HER2-positive metastatic breast cancer

ASCO 2018: highlights in HER2-positive metastatic breast cancer

ASCO 2018: highlights in HER2-positive metastatic breast cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer

New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma

New Systemic Therapy Strategies for HER2-Positive Metastatic Breast Carcinoma

Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer

Current Standards and Future Outlooks in Metastatic Her2-Positive Breast Cancer

Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016

Cost of illness of HER2-positive and metastatic and recurrent HER2-positive breast cancer – a Danish register-based study from 2005 to 2016

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer

New Therapeutic Strategies in Advanced Nonoperable or Metastatic HER2-positive Breast Cancer

Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update

Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer

Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte

Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte

PYK2 promotes HER2-positive breast cancer invasion

PYK2 promotes HER2-positive breast cancer invasion

Related objects